

May 18, 2018  
Symbio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

### **TREAKISYM® Sales Forecast for FY2018**

TOKYO, Japan, May 18, 2018 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, “Symbio” or the “Company”) announced today that after publication by its marketing partner Eisai Co., Ltd. (“Eisai”) of its FY2018 sales forecast for TREAKISYM® in the reference data to Eisai’s FY2017 financial reports on May 15, 2018, which varied from Symbio’s own forecast, Symbio has reaffirmed the forecast of NHI drug price-based sales for TREAKISYM® in FY2018 with Eisai.

(\*)[www.eisai.com/ir/library/settlement/pdf/e2018Q4\\_52.pdf](http://www.eisai.com/ir/library/settlement/pdf/e2018Q4_52.pdf)

Symbio has reaffirmed with Eisai that there is no change in the forecast for NHI drug price-based sales of ¥10.1 billion for FY2018, which is based on an agreement with Eisai. This forecast is in line with Symbio’s forecast of ¥4.2 billion in sales for FY2018, announced on February 7, 2018. Accordingly, there is no change to the Company’s FY2018 forecast.

Symbio, looking toward its second inauguration in 2020, will continue to expand its business with the aim of achieving a market penetration rate of 80% for 1<sup>st</sup> line NHL of TREAKISYM® by the end of 2020, by establishing TREAKISYM® as the standard therapy in the field of Low-Grade Non-Hodgkin Lymphoma (NHL).

#### **[Contact]**

Investor Relations

Tel: +81 (0)3 5472 1125

#### **About Symbio Pharmaceuticals Limited**

Symbio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 Symbio incorporated its wholly-owned subsidiary in the U.S., Symbio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). Symbio’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.